Release Date: November 12, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What are the key data points investors should focus on regarding the upcoming data update for CARTITUDE-1 and IMAgINE-1 trials? A: Ying Huang, CEO, explained that the IMAgINE-1 trial involves a less sick patient population compared to CARTITUDE-1. Key metrics include the number of prior lines of therapy and refractory patient populations. Efficacy is measured by ORR and CR rates, with CARTITUDE-1 showing a 97% ORR and 67% CR rate. Durability and PFS are crucial, with nearly three years' PFS in CARTITUDE-1. Safety management strategies are also discussed, including patient selection and proactive management.
Q: How should we think about quarter-over-quarter growth going into Q4, and is there an FDA cap on CAR-T production? A: Ying Huang, CEO, confirmed expectations for sequential growth in Q4, although no quantitative guidance was provided. Regarding FDA regulation, both CARVYKTI and Abecma have experienced capacity regulation by the FDA, which applies to all CAR-T manufacturing facilities. Legend Biotech has been able to supply the market effectively, achieving the highest revenue and slots among commercial CAR-T brands.
Q: Can you elaborate on the ramp-up cadence for the second-line launch and the expected shift in CARVYKTI use from late to early lines? A: Steve Gavel, SVP of Commercial Development, stated that the majority of patients treated will be in the CARTITUDE-4 population, with a two-thirds to one-third ratio expected by next year. The early line adoption is ahead of expectations, driven by recent overall survival data, and this trend is expected to continue.
Q: How is the evolution of inpatient versus outpatient use of CARVYKTI progressing, and what drives this shift? A: Steve Gavel, SVP of Commercial Development, explained that the shift to outpatient use is driven by the need to manage increased patient volumes in the second line plus setting. Major academic sites are leading this adoption, with outpatient use reaching up to 50% in some locations. The delayed CRS onset of CARVYKTI facilitates outpatient administration, allowing for remote monitoring and later hospital admission if needed.
Q: What are the expectations for Europe now that commercial capacity is up and running, and how do European physicians select CAR-T over other options? A: Steve Gavel, SVP of Commercial Development, noted that the European market differs from the U.S., with slower CAR-T adoption due to pricing agreements. Germany is the key driver for CARVYKTI in Europe. Ying Huang, CEO, added that survival data is crucial for European single-payer systems, and CARVYKTI's demonstrated survival benefit is a significant advantage in discussions with European agencies.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.